NKS TRADING TRICKS💎

VEDANTA: Vedanta Halts Bond Sale Plans Amid Adani Market Turmoil: Bloomberg

Adani; Solar Energy Corp Head Says Have Not Got Any Docs Over Charges By U.S. - Reuters

Not Clear If Any Of Solar Energy Corp's 'Covenants' Have Been Violated

No Basis' To Investigate Matter w.r.t Charges On Adani GroupVEDANTA: Vedanta Halts Bond Sale Plans Amid Adani Market Turmoil: Bloomberg

ADANI STOCKS VALUATION

Adani Ent
7 Yr Median PE: 112x
Present PE: 47x

Adani Port
7 Yr Median PE: 28.6x
Present PE: 24x

Adani Green
7 Yr Median PE: 264x
Present PE: 146x

Adani Power
7 Yr Median PE: 10x
Present PE: 15x

Adani Energy
7 Yr Median PE: 89x
Present PE: 57x

Ambuja Cem
7 Yr Median PE: 27x
Present PE: 42x

Adani Total
7 Yr Median PE: 175x
Present PE: 95x

Adani Wilmar
7 Yr Median PE: 84x
Present PE: 36x

ACC
7 Yr Median PE: 21x
Present PE: 21x

BHARAT PRENTERAL ; Innoxel Lifescience, a subsidiary of Bharat Parental Limited (BPL), has out-licensed a complex injectable drug to a leading generic pharma MNC.

With a market size of $500M (as of March 2024), Innoxel will earn $4.5M in milestones during ANDA filing and 20% profit sharing post-launch.

The deal highlights Innoxel's strength in complex drug development.

Innoxel has partnered for a $400M oral liquid 505(b)(2) NDA opportunity, earning $1.95M in milestones during USFDA filing and 45% profit sharing post-launch.

Parent company Bharat Parenterals Ltd., based in Vadodara, specializes in high-quality, affordable pharmaceutical formulations, excelling in injectables.

MARCO CABLE ; WINS RS 10.43 CR ORDER

Co. Got two purchase order received from reputed client of cable Industry for supply of L.T. Aerial bunched cable. Total order value is Rs. 10,43,20,260/- Inclusive of all taxes.

NATCO has filed an ANDA with a paragraph IV certification for the generic version of EVRYSDI® (Risdiplam) 0.75 mg/mL oral solution with the FDA.

The company believes it is among the first two filers and may qualify for 180 days of shared exclusivity. Genentech and partners have sued NATCO in a New Jersey court.

EVRYSDI® has recorded sales of USD 571 million in the US market for the year 2023*.

JustIN | Monitoring charges brought by US Attorney’s office against GautamAdani & other AdaniGroup executives. Will review Adani details to determine any portfolio actions

CITI INDIA STRATEGY

• Post 10% correction in NIFTY, valuations are more reasonable

• NIFTY 1-year forward P/E now just slightly above 5-year long term average

• Q2 earnings was weak in consumer sectors, but status quo in most others

• Decent double-digit growth in Financials, Industrials, Healthcare & Telc

• See potential H2 recovery in public capex & rural demand are positives D

• Urban consumption & asset quality remains a watch Watch

• Domestic Flows continue to be robust, but sentiment may be tested if FII sell-off sustains

• Upgrade Cement to Overweight from Neutral post the underperformance since mid-CY24 and expectations of volume pickup in H2 as well as likely bottoming out of EBITDA/ton metric

• Add Ramco Cement and switch from Devyani to Jubilant Food in our mid-cap picks

• Key Overweight: Financials, Telecom, Pharma

• Key Underweight: Consumer Discretionary, IT, Metals

• Sep'25 NIFTY target is 25k - 7% upside from here

JPMORGAN ON STEEL

• India's coking coal imports & domestic coking coal production growth slowed down in H1FY25

• Slow down due to a combination of steel production disruption, inventory correction, election-related slowdown & monsoon impact

• India is now importing a substantial share of coking coal from Russia (lower priced)

• Believe Indian steel prices have found a floor

• Meaningful uptick looks unlikely in the near term

• Steelmakers could continue to optimize coking coal costs by diversifying their suppliers

• Prefer JSW Steel, Tata Steel; Neutral on SAIL and Coal India